CARGO Therapeutics, Inc. Common Stock (CRGX) Stock Analysis & Investment Frameworks
CARGO Therapeutics, Inc. Common Stock (CRGX) stock analysis on Invetso. Review CARGO Therapeutics, Inc. Common Stock’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
CARGO Therapeutics, Inc. Common Stock Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
CARGO Therapeutics, Inc. Common Stock Key Financial Metrics
- Market Cap: $216.19M
- Revenue: $N/A
- ROE: -43.76%
- ROIC: -48.09%
- Dividend Yield: N/A
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.